Teneliximab
Based on 1 Customer Validation
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : ≥99.0%
- No. CAS: 299423-37-3
- Peso molecular:146.06 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD40
In Vitro
The effects of Teneliximab (Chi220, BMS-224819) are not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Gene ID
Accession
P25942-1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Raji cells labelling CD40 (red) with Teneliximab (anti-CD40) (HY-P99321). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
No. CAS 299423-37-3
-
Appearance Liquid
-
Peso molecular 146.06 kDa
-
Color Colorless to light yellow
-
SMILES
[Teneliximab]
-
Synonyms
BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Maria A Argiriadi, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20(1):29. [Content Brief]
[2]. Andrew B Adams, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005 Jan 1;174(1):542-50. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)